Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

PURPOSE: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Karp, Judith E., Thomas, Brian M., Greer, Jacqueline M., Sorge, Christopher, Gore, Steven D., Pratz, Keith W., Smith, B. Douglas, Flatten, Karen S., Peterson, Kevin, Schneider, Paula, Mackey, Karen, Freshwater, Tomoko, Levis, Mark J., McDevitt, Michael A., Carraway, Hetty E., Gladstone, Douglas E., Showel, Margaret M., Loechner, Sabine, Parry, David A., Horowitz, Jo Ann, Isaacs, Randi, Kaufmann, Scott H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3596113/
https://ncbi.nlm.nih.gov/pubmed/23092873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2442
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados